Effect of l-ornithine l-aspartate against thioacetamide-induced hepatic damage in rats

被引：20

作者：

Najmi, Abul K. ^{[1
]}

Pillai, K. K. ^{[1
]}

Pal, S. N. ^{[3
]}

Akhtar, M. ^{[1
]}

Aqil, M. ^{[2
]}

Sharma, M. ^{[1
]}

机构：

[1] Hamdard Univ, Dept Pharmacol, Fac Pharm, New Delhi 110062, India

[2] Hamdard Univ, Dept Pharmaceut, Fac Pharm, New Delhi 110062, India

[3] WHO, CH-1211 Geneva 27, Switzerland

来源：

INDIAN JOURNAL OF PHARMACOLOGY | 2010年 / 42卷 / 06期

关键词：

Hepatopathy; ornithine aspartate; oxidative stress; thioacetamide; DIETARY NUCLEOTIDES; ENCEPHALOPATHY; CIRRHOSIS; MANAGEMENT; EFFICACY; AMMONIA; ENZYMES;

D O I：

10.4103/0253-7613.71926

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Objective: To investigate the hepatoprotective activity of L-ornithine-L-aspartate against thioacetamide (TAA)-induced hepataopathy in rats. Materials and Methods: The hepatoprotective activity of L-ornithine-L-aspartate (OA) at a dose of 2 g/kg, p.o. for 10 days was evaluated against TAA (250 mg/kg, i.p. for 2 days) induced hepatopathy in rats. Biochemical parameters such as serum aspartate transaminase, alanine transaminase, alkaline phosphatase, bilirubin and glutathione, thiobarbituric acid reactive substances, and protein in liver tissues were estimated to assess the liver function. Results: TAA-induced pathogenic changes in the levels of the above indices were significantly (P < 0.01) reversed by the OA treatment. OA treatment also exhibited significant restoration of the hepatic architecture and lobular structure in histological evaluation of the rat liver sections. Conclusion: Ornithine aspartate exhibited significant hepatoprotective activity against TAA-induced hepatic damage in rats.

引用

页码：384 / 387

页数：4

共 50 条

[31] L-ornithine L-aspartate for hepatic encephalopathy: a systematic review with meta-analyses of randomised controlled trials
Goh, E. T.
Stokes, C. S.
Vilstrup, H.
Gluud, L. L.
Morgan, M. Y.
JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S131 - S131
[32] PICROLIV AFFORDS PROTECTION AGAINST THIOACETAMIDE-INDUCED HEPATIC DAMAGE IN RATS
DWIVEDI, Y
RASTOGI, R
SHARMA, SK
GARG, NK
DHAWAN, BN
PLANTA MEDICA, 1991, 57 (01) : 25 - 28
[33] L-Aspartate, L-Ornithine and L-Ornithine-L-Aspartate (LOLA) and Their Impact on Brain Energy Metabolism (vol 45, pg 1438, 2020)
Das, Abhijit
Frohlich, Dominik
Achanta, Lavanya B.
Rowlands, Benjamin D.
Housley, Gary D.
Klugmann, Matthias
Rae, Caroline D.
NEUROCHEMICAL RESEARCH, 2020, 45 (10) : 2527 - 2527
[34] Hepatoprotection by L-Ornithine L-Aspartate in Non-Alcoholic Fatty Liver Disease
Butterworth, Roger F.
Canbay, Ali
DIGESTIVE DISEASES, 2019, 37 (01) : 63 - 68
[35] l-Ornithine l-Aspartate (LOLA) for Hepatic Encephalopathy in Cirrhosis: Results of Randomized Controlled Trials and Meta-Analyses
Roger F. Butterworth
Mark J. W. McPhail
Drugs, 2019, 79 : 31 - 37
[36] L-Ornithine L-Aspartate (LOLA) for Hepatic Encephalopathy in Cirrhosis: Results of Randomized Controlled Trials and Meta-Analyses
Butterworth, Roger F.
McPhail, Mark J. W.
DRUGS, 2019, 79 (Suppl 1) : 31 - 37
[37] EFFECT OF HYPOTHERMIA ON THIOACETAMIDE-INDUCED HEPATIC DAMAGE
MOLNAR, Z
VARGA, F
ACTA PHYSIOLOGICA ACADEMIAE SCIENTIARUM HUNGARICAE, 1968, 34 (1-2): : 95 - &
[38] L-ornithine L-aspartate in acute treatment of severe hepatic encephalopathy: A double-blind randomized controlled trial
Jain, Arpan
Sharma, Barjesh Chander
Mahajan, Bhawna
Srivastava, Siddharth
Kumar, Ajay
Sachdeva, Sanjeev
Sonika, Ujjwal
Dalal, Ashok
HEPATOLOGY, 2022, 75 (05) : 1194 - 1203
[39] L-ornithine L-aspartate as hepatoprotective agent in acute viral hepatitis in HIV positive patients
Dalal, B
Dalal, P
Desai, H
Madan, T
Goplani, K
JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 42 (09): : 1055 - 1055
[40] L-Ornithine L-Aspartate for the Treatment of Sarcopenia in Chronic Liver Disease: The Taming of a Vicious Cycle
Butterworth, Roger F.
CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2019, 2019

← 1 2 3 4 5 →